Skip to main content

What's new

Two diabetes devices from Medtronic – a next-gen continuous glucose monitor that removes fingerstick calibrations and a smart insulin delivery pen that keeps track of your insulin doses – will become available in Europe later this year. The two can share data with one another to simplify diabetes management for people on multiple daily injections of insulin. Continue Reading »

Bigfoot Biomedical’s new diabetes management system will provide insulin dosing recommendations based on glucose data and a healthcare professional’s instructions to people with diabetes who take multiple daily injections of insulin. Continue Reading »

Omada Health is launching a physician-guided care program for people with diabetes and high blood pressure. Through the app, members will have access to physicians, health coaches, and diabetes care and education specialists, and will be able to see their health data and make medication changes. Continue Reading »

If you just got a continuous glucose monitoring system, you may be wondering how to use it most effectively and how to understand your glucose data. Read our tips, tricks, and things to consider. Continue Reading »

Two studies recently published on the Control-IQ and MiniMed 780G systems show that closed-loop automated insulin delivery significantly improves Time in Range. Continue Reading »

Medtronic’s Extended insulin infusion set doubles the wear-time of a traditional infusion set. The device is launching in Finland and Belgium, with other European countries coming later this year. Continue Reading »

Calling all adults with prediabetes or type 2 diabetes: The T2Help study is recruiting 280 participants for a 16-week virtual clinical trial to collect continuous glucose monitor (CGM), activity tracker, and self-recorded health data.  Continue Reading »

A fully virtual six-month clinical trial is recruiting 300 people with type 1 and type 2 diabetes who are interested in trying continuous glucose monitoring (CGM) with personal support. The study will determine how access to virtual diabetes care with CGM impacts Time in Range (TIR). Continue Reading »

Pages